Publications
Publications
Show Results For
- All HBS Web
(632)
- Faculty Publications (243)
- July 2000 (Revised April 2001)
- Case
Agricultural Biotechnology and its Regulation
In the United States, genetically modified corn and soybeans are now widely grown and consumed. In Europe, however, they have been dubbed "Frankenstein foods," shunned by packaged food manufacturers, and subjected to a host of governmental restrictions. This case... View Details
- 27 Mar 2000
- Conference Presentation
Biotechnology Industry Organization Paper
By: Michael Porter
Keywords: Biotechnology Industry
- February 2000 (Revised October 2000)
- Case
Kendle International Inc.
By: Dwight B. Crane, Paul W. Marshall and Indra Reinbergs
Candace Kendle and Christopher Bergen, the CEO and COO of Kendle International, Inc., are reviewing ways to finance the growth of their privately-owned company. Kendle is a contract research organization that conducts clinical drug trials for pharmaceutical and... View Details
- December 1999 (Revised August 2001)
- Case
Millennium Pharmaceuticals, Inc. (A)
By: Stefan H. Thomke and Ashok Nimgade
Focuses on Millennium's strategy to grow and revolutionize drug development through the use of new technologies such as genomics. Describes how Millennium Pharmaceuticals--a fast-growing biotechnology firm in Cambridge, MA--has used strategic alliances to finance the... View Details
- November 1999
- Case
Seminis Inc.
By: Ray A. Goldberg, Jonathan West, Carin-Isabel Knoop and David Benedict Pearcy
Seminis became the world leader in vegetable seeds through a series of acquisitions. This case describes the Seminis strategy toward capturing value, biotechnology, and international operations. View Details
- October 1999
- Case
Agricultural Biotechnology Brief, 1999
By: Forest L. Reinhardt and Jennifer Burns
- May 1999
- Teaching Note
Elliot Lebowitz TN
By: Paul A. Gompers
Teaching Note for (9-297-094). View Details
Keywords: Biotechnology Industry
- May 1999
- Teaching Note
Genset Initial Public Offering (A) & (B) TN
By: Paul A. Gompers
Teaching Note for (9-297-096) and (9-297-097). View Details
- May 1999
- Teaching Note
Genset: 1989 TN
By: Paul A. Gompers
Teaching Note for (9-298-070). View Details
- October 1998 (Revised December 1999)
- Case
Gene Research, the Mapping of Life and the Global Economy
By: Ray A. Goldberg and Juan Enriquez-Cabot
A new firm is being created to speed up the process of mapping humans, animals, and plants by combining gene technology with rapid gene identification to improve the health and well being of the human population and the productivity of crops and animals. How does one... View Details
- September 1998
- Case
Monsanto's March into Biotechnology (C)
By: Dorothy A. Leonard and Robert Irwin
Supplements the (A) and (B) cases. View Details
- Article
The Control of Technology Alliances: An Empirical Analysis of the Biotechnology Industry
By: Josh Lerner and Robert P. Merges
- January 1998 (Revised September 2001)
- Case
Genset: 1989
By: Paul A. Gompers and Amy Burroughs
Discusses the start-up strategy at Genset, a French biotech firm. Pascal Brandys, a venture capitalist, and Marc Vasseur, a leading French scientist, must decide how to proceed. Future real options are central to the strategy. View Details
- October 1997
- Case
Roslin Institute, The
By: Ray A. Goldberg and Tom Clay
Dr. Ian Willmut and the Roslin Institute have developed a revolutionary new technology--cloning. Now they are faced with some tough choices concerning going forward. How should they balance commercialization opportunities with societal concerns? View Details
- September 1997 (Revised October 1997)
- Case
Bayer AG (A)
By: John A. Quelch
Bayer's senior executives convene in Germany to consider submitting a $1 billion bid that would recover the Bayer brand name and trademark cross in North America, both of which were confiscated by the U.S. government after World War I. The group also sets out to assess... View Details
- September 1997
- Case
Bayer AG (B)
By: John A. Quelch
Bayer's senior executives detail the communications challenge program that resulted from the company's reacquisition of its brand name and trademark cross, which gave Bayer one name worldwide for the first time since World War I. View Details
- June 1997 (Revised October 2001)
- Case
Elliot Lebowitz
By: Paul A. Gompers and Alexander Tsai
Elliot Lebowitz, president and CEO of BioTransplant, must decide on a strategy for this young biotechnology start-up. Among the issues to be resolved are focus of research and search for strategic alliance partners. View Details
- June 1997 (Revised March 2001)
- Case
Genset Initial Public Offering (A)
By: Paul A. Gompers and Jeffrey M. Anapolsky
Pascal Brandys, founder and CEO of Genset, must decide whether to take this young biotechnology company public. If so, should he do a dual offering in both France and the U.S.? The case also explores the business models in genomics research. View Details
- June 1997 (Revised September 1997)
- Case
Genset Initial Public Offering (B)
By: Paul A. Gompers and Jeffrey M. Anapolsky
Supplements the (A) case. View Details